New drug combo aims to shrink tumors before surgery, kill remaining cells after
NCT ID NCT05775471
Summary
This study is testing a two-part treatment for high-risk cancer of the kidney's drainage system (upper tract urothelial carcinoma). It gives patients a combination of two immunotherapy drugs (pembrolizumab and enfortumab vedotin) before surgery to remove the kidney and ureter, aiming to shrink the tumor. After surgery, patients receive more pembrolizumab to try to kill any cancer cells left behind and prevent the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL PELVIS AND URETER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.